Deerfield Management Company, L.P. (Series C) Biocryst Pharmaceuticals Inc Transaction History

Deerfield Management Company, L.P. (Series C)

$4.35 Billion
Q2 2025

A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 4,692,000 shares of BCRX stock, worth $39.2 Million. This represents 0.97% of its overall portfolio holdings.

Number of Shares

4,692,000

Previous 5,189,665 9.59%

Holding current value

$39.2 Million

Previous $38.9 Million 8.01%

% of portfolio

0.97%

Previous 0.99%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.41 - $11.19 $3.19 Million - $5.57 Million	-497,665 Reduced 9.59%	4,692,000 $42 Million
Q1 2025 May 15, 2025	SELL	$7.06 - $9.39 $20.9 Million - $27.7 Million	-2,954,777 Reduced 36.28%	5,189,665 $38.9 Million
Q4 2024 Feb 14, 2025	BUY	$7.03 - $8.43 $60,725 - $72,818	8,638 Added 0.11%	8,144,442 $61.2 Million
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $13 Million - $21.3 Million	3,140,804 Added 62.88%	8,135,804 $50.3 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $2.23 Million - $3.48 Million	455,475 Added 10.03%	4,995,000 $25.4 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $6.24 Million - $8.49 Million	1,253,525 Added 38.15%	4,539,525 $27.2 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $13.2 Million - $15.6 Million	1,964,000 Added 148.56%	3,286,000 $23.3 Million
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $10 Million - $12.7 Million	-1,443,000 Reduced 52.19%	1,322,000 $9.31 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $22 Million - $32.7 Million	2,765,000 New	2,765,000 $23.1 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $7.98 Million - $18.1 Million	-1,012,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $7.79 Million - $13.3 Million	-674,140 Reduced 39.98%	1,012,000 $16.5 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $16.2 Million - $22.4 Million	1,451,497 Added 618.6%	1,686,140 $23.4 Million
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $37 Million - $45.9 Million	-2,600,357 Reduced 91.72%	234,643 $3.37 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $2.18 Million - $3.96 Million	229,620 Added 8.81%	2,835,000 $44.8 Million
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $23.8 Million - $44 Million	-3,230,430 Reduced 55.36%	2,605,380 $26.5 Million
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $4.65 Million - $11.9 Million	1,379,291 Added 30.95%	5,835,810 $43.5 Million
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $373,173 - $1.1 Million	-196,407 Reduced 4.22%	4,456,519 $21.2 Million
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $2.76 Million - $7.08 Million	-1,722,217 Reduced 27.01%	4,652,926 $9.31 Million
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $5.72 Million - $12.4 Million	3,600,500 Added 129.76%	6,375,143 $22 Million
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $8.8 Million - $13.1 Million	-3,518,337 Reduced 55.91%	2,774,643 $7.95 Million
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $711,745 - $2.24 Million	-244,586 Reduced 3.74%	6,292,980 $23.9 Million
Q1 2019 May 15, 2019	SELL	$7.38 - $9.72 $2.75 Million - $3.63 Million	-373,223 Reduced 5.4%	6,537,566 $53.2 Million
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $4.68 Million - $6.77 Million	847,293 Added 13.97%	6,910,789 $52.7 Million
Q2 2018 Aug 14, 2018	SELL	$4.6 - $6.52 $5.99 Million - $8.5 Million	-1,302,964 Reduced 17.69%	6,063,496 $34.7 Million
Q1 2018 May 15, 2018	BUY	$4.35 - $5.82 $665,841 - $890,849	153,067 Added 2.12%	7,366,460 $35.1 Million
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $9.31 Million - $11.9 Million	2,237,942 Added 44.98%	7,213,393 $35.4 Million
Q3 2017 Nov 13, 2017	BUY	$4.1 - $5.97 $20.4 Million - $29.7 Million	4,975,451	4,975,451 $26.1 Million

Others Institutions Holding BCRX

# of Institutions

315

Shares Held

202M

Call Options Held

928K

Put Options Held

560K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.55B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account

Deerfield Management Company, L.P. (Series C) Biocryst Pharmaceuticals Inc Transaction History